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versus chemoradiotherapy alone in patients with locally advanced
cervical cancer
Yoko Harimaa, Takayuki Ohgurib, Hajime Imadac, Hideyuki Sakuraid, Tatsuya Ohnoe, Yoshiyuki Hirakif, Koh Tujig,
Masahiro Tanakah and Hiromi Terashimai
aDepartment of Radiology, Kansai Medical University, Moriguchi City, Japan; bDepartment of Radiology, University of Occupational and
Environmental Health, Kitakyusyu City, Japan; cCancer Therapy Center, Tobata Kyoritsu Hospital, Kitakyusyu City, Japan; dDepartment of
Radiation Oncology, University of Tsukuba, Tsukuba City, Japan; eDepartment of Radiation Oncology, Gunma University Heavy Ion Medical
Center, Maehashi City, Japan; fDepartment of Radiology, Kagoshima University, Kagoshima City, Japan; gDepartment of Radiology, National
Hospital Organization Minami Wakayama Medical Center, Tanabe City, Japan; hDepartment of Radiation Oncology, Osaka City General
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ABSTRACT
Purpose: To evaluate the effectiveness of whole-pelvic hyperthermia (HT) added to standard chemora-
diotherapy (CRT) in locally advanced cervical cancer (CC), by investigating the clinical response and sur-
vival of patients treated with cisplatin-based CRT vs. CRT with HT (CRTþHT).
Materials and methods: This study was conducted at five hospitals in Japan between September
2001 and March 2015 in patients with the International Federation of Gynecology and Obstetrics stage
IB (bulky)–IVA CC undergoing definitive CRT. After giving a written informed consent, patients were
randomly allocated to two treatment groups: CRT and CRTþHT group. Overall survival (OS), disease-
free survival (DFS), local relapse-free survival (LRFS), complete response (CR) rate and tolerability were
evaluated.
Results: In total, 101 patients were treated. Patient characteristics, total dose of cisplatin and radiother-
apy were similar for both groups. Although not statistically significant, the 5-year OS, DFS and LRFS in
the CRTþHT group (77.8%, 70.8% and 80.1%, respectively) were better than those in the CRT group
(64.8%, 60.6% and 71.0%, respectively). CR was significantly more likely to be achieved in patients in
the CRTþHT group than in the CRT group (88% vs. 77.6%; adjusted odds ratio, 3.993; 95% confidence
interval, 1.018–15.67; p¼ .047). CRTþHT was well tolerated and caused no additional acute or long-
term toxicity compared with CRT alone.
Conclusions: HT combined with CRT improved the CR rate of CRT in patients with locally advanced
CC, however, could not improve survival outcomes. Further studies in larger samples are warranted.
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Introduction
Cervical cancer (CC) is one of the most common types of
cancer, both in incidence and mortality, affecting women
worldwide [1]. In patients with early stage CC, radical surgery
can be an effective treatment modality, whereas in patients
with more advanced stage CC, cisplatin-based concomitant
chemoradiotherapy (CRT) is generally administered. So far,
five large-sample randomised studies have demonstrated the
efficacy of CRT [2–6].
Hyperthermia (HT) has also been shown to be effective in
the treatment of CC [7]. Two randomised phase III trials com-
paring patient groups receiving radiotherapy (RT) or RTþHT
as a primary treatment for locally advanced CC showed
higher complete response (CR) rates and better overall sur-
vival (OS) in the combination therapy group [8,9].
Furthermore, it was reported that HT enhanced the activity
of chemotherapy, particularly that with cisplatin [10]. The
combination of cisplatin chemotherapy and loco-regional HT
improved response rates and survival in patients with recur-
rent CC with no additional toxicity [11,12].
The findings of these studies suggest that a combination
of all three treatments (RT, chemotherapy and HT) could fur-
ther yield better clinical outcomes in patients with locally
advanced CC. According to Westermann et al. [13], in 68
patients prospectively registered in the USA, Norway and the
Netherlands and treated with a combination of RT, weekly
cisplatin and loco-regional HT, 5-year relapse-free survival
and 5-year OS were similar or better compared with those in
patients treated with standard CRT. However, there has been
no randomised clinical trial comparing CRTþHT with CRT
alone in patients with advanced CC.
Here, we report a Japanese multicentre randomised clin-
ical trial of concurrent CRTþHT vs. CRT alone to evaluate
the effectiveness and safety of this combination therapy in
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the daily clinical settings in patients with locally advanced
CC.
Materials and methods
Patients
The present study was a prospective, multicentre, rando-
mised, parallel-group study conducted at five Japanese
institutions by the Japanese Society of Hyperthermic
Oncology (JASHO) group between September 2001 and
March 2015.
The study was conducted in accordance with the princi-
ples of the Declaration of Helsinki. The study protocol was
approved by the Kansai Medical University Review Board. All
participants signed an informed consent form approved by
each centre’s institutional review board.
Consecutive patients with CC were screened for enrolment
in the study. The eligibility criteria were as follows:
 International Federation of Gynecology and Obstetrics
(FIGO) stages [14] IB bulky (4 cm diameter), IIA, IIB, IIIA,
IIIB or IVA;
 Eastern Cooperative Oncology Group (ECOG) performance
status 0–2;
 no history of RT, chemotherapy or surgery;
 para-aortic lymph nodes negative for metastasis;
 no double cancer;
 no pacemaker;
 adequate haematologic function: leukocyte count 3000/
lL, platelet count 100 103/lL and haemoglobin level
10.0 g/dL;
 adequate renal, hepatic and cardiac functions as well as
levels of glutamic oxaloacetic transaminase and glutamic
pyruvic transaminase 35 IU/L, total bilirubin 1.5mg/dL
and serum creatinine 0.8mg/dL, with creatinine clear-
ance 60mL/min and normal electrocardiogram or elec-
trocardiographic changes (not requiring treatment);
 feasibility of cisplatin treatment;
 feasibility of HT;
 written informed consent.
Exclusion criteria included the following:
 pregnancy or lactation;
 distant metastasis;
 serious, uncontrolled concurrent medical or neurologic
conditions;
 chronic heart failure or heart failure in the previous 3
months;
 cerebral vascular disorder in the previous 3 months;
 active infection.
Pre-randomisation evaluation included taking a medical
history and physical examination, blood chemistry profile,
chest radiograph, computed tomography (CT), magnetic
resonance imaging (MRI), fluorodeoxyglucose-positron emis-
sion tomography/contrast-enhanced CT and biopsy.
Treatment
Chemoradiotherapy
Whole-pelvis radiotherapy was provided using 6- or 10-MV
high-energy linear accelerators. An additional dose was
given to the parametria with central shielding. The radi-
ation was delivered to the tumour in fractions of 1.8–2Gy
daily, 5 days per week, with a standard 2- or 4-technique.
Intensity-modulated radiotherapy was not permitted in this
study. The patients additionally received 192Ir high-dose-
rate intracavitary brachytherapy. The 192Ir brachytherapy
was given to point A (2 cm lateral to the central canal of
the uterus and 2 cm above the mucous membrane of the
lateral fornix in the axis of the uterus) [15] at a dose of
5–6Gy per session once per week. Additionally, patients
were treated weekly with cisplatin at a dose of 30–40mg/
m2 for 3–5 cycles.
Hyperthermia
Regional whole-pelvis HT was administered on a weekly basis
concurrent with cisplatin-CRT, but not with brachytherapy.
Treatment was given in succession in the following order: cis-
platin, RT and HT. For all HT treatments, HT was delivered via
a radiofrequency capacitive heating device (Thermotron RF-8,
Yamamoto Vinita Com, Osaka, Japan), which uses 8MHz
radiofrequency electromagnetic waves as a source of heat.
The output power ranged from 800 to 1500 W. Deep
regional HT was applied within 30min of external RT for
60min once a week during an external beam RT course. For
thermometry, a 4-point micro-thermocouple sensor was
placed in the rectum and vagina. The heating procedure was
carried out as previously described [9]. The maximum tumour
temperature (Tmax) was defined as the maximum temperature
obtained in the rectum and vagina during the steady state at
the end of treatment. All parameters were determined for
each treatment session, and the averages of these parame-
ters (Tave) were calculated over all treatments for a given
tumour. In addition, the cumulative equivalent minutes at
43 C for T90 (CEM43T90) were obtained as described by
Fatehi et al. [16] during all sessions with temperature
measurements.
Evaluation of treatment
The primary endpoint was 5-year OS. The secondary end-
points included CR rate, 5-year disease-free survival (DFS),
5-year local relapse-free survival (LRFS) and acute- or late-
phase toxicity. OS (all-cause death as an outcome event), DFS
(all-cause death, local relapse or distant metastasis as out-
come events) and LRFS (local relapse as an outcome event)
were estimated as months from the enrolment to the date of
occurrence of the outcome events or to the date of the last
observation for patients who were censored. Regarding DFS
and LRFS, non-CR of the tumour was considered as local
relapse on the day the patient completed study treatment.
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CR was achieved when no tumour was detected on
physical examination or MRI, with cytology or biopsy
results negative for malignant cells for at least 1 month
after the treatment. CR rate was calculated using the num-
ber of patients who achieved CR as the numerator and
the number of evaluated therapeutic responses as the
denominator.
Acute-phase treatment-related toxicity was graded accord-
ing to a modification of the Radiation Therapy Oncology
Group (RTOG) morbidity scale [17]. Clinical items and graded
adverse events included haemoglobin, white blood cell
count, platelet count, nausea, vomiting, diarrhoea, urinary,
weight loss, fatigue, nephrotoxicity, and HT-related blistering
and fat necrosis.
Patients were examined every month during 1 year of
treatment and every 2 months thereafter. CR rate and acute-
phase toxicity were evaluated 1 month after the completion
of protocol treatment, and OS, DFS, LRFS and late-phase tox-
icity were assessed during the follow-up period until March
2015.
Study design
Eligible participants were randomised at the central data
centre before the initiation of treatment according to a com-
puter-generated random number list into two treatment
groups: those treated with CRT alone and those treated with
CRTþHT. The sample size was calculated to detect a differ-
ence in CR rates between the groups, assuming a CR rate of
50% for the CRT group and 80% for the CRTþHT group
based on the results of our previous study [9]. Fisher’s exact
test with a 0.05 two-sided significance level would have an
80% power if the sample size in each group was 44.
Allowing for a certain number of dropouts, a sample size of
50 patients for each group was determined.
Statistical analysis
To evaluate the effectiveness and safety of the protocol treat-
ments in a daily clinical setting, the intent-to-treat approach
was applied for statistical analysis. Patient characteristics
were summarised as mean (range) for continuous variables
and as number (%) for categorical variables. Clinical items for
tabulation were as follows: age, tumour size, FIGO stage, hist-
ology, treatment duration, total dose of RT (external RT and
brachytherapy), frequency of chemotherapy, total dose of cis-
platin, number of HT treatments and thermometry results
(Tmax, Tave and CEM43T90) for the CRTþHT group, and fol-
low-up duration. Survival rates were estimated using the
Kaplan–Meier method [18] and differences in the 5-year sur-
vival between the treatments were examined using the log-
rank test [19]. Further analyses were conducted for survival
outcomes by using multivariable Cox proportional hazards
models [20] adjusting for known clinical factors (age, FIGO
stage and histology). Adjusted hazard ratio (HR) and 95%
confidence interval (CI) of the CRTþHT group (reference:
CRT group) for each outcome was estimated and tested for
significance.
The association of CR rate with treatment groups was
examined using cross tabulation and Fisher’s exact test.
Further analysis was conducted for CR rate using a multivari-
able logistic regression model [21] with treatment group as
an independent variable and age, FIGO stage and histology
as adjusting covariates. Adjusted odds ratio (OR) and 95% CI
of the CRTþHT group for CR were estimated and tested for
significance.
Acute-/late-phase treatment-related toxicity was summar-
ised as the number (%) of adverse events.
All statistical analyses were performed using IBM SPSS
Statistics 23.0 (IBM Corp., Armonk, NY). A two-sided p value
below .05 was considered significant for all statistical tests.
Results
Patient characteristics
In total, 101 Japanese patients with CC with a mean age of
61.0 years (range, 24–87 years) fulfilled the eligibility criteria
and were enrolled in the study from 3 September 2001 to
10 September 2013. Fifty patients (mean age, 62.1 years;
range, 24–82) were randomised into the CRT group and 51
(mean age, 59.9 years; range, 30–87) were randomised into
the CRTþHT group. Patients’ demographic characteristics,
total dose of cisplatin and RT were similar in both groups
(Table 1). Median follow-up durations for the CRT and
CRTþHT groups were 47.1 and 63.1 months, respectively.
Table 1. Patient characteristics.
CRT (n¼ 50) CRTþHT (n¼ 51)
Mean (range), n (%)
Age (years) 62.1 (24–82) 59.9 (30–87)
Tumour size (cm) 5.5 (2.6–8.6) 5.8 (3.2–14)
FIGO stage
IIA 1 (2.0) 0
IIB 14 (28.0) 12 (23.5)
IIIA 2 (4.0) 0
IIIB 29 (58.0) 35 (68.6)
IVA 4 (8.0) 4 (7.8)
Histology
Squamous cell carcinoma 47 (94.0) 43 (84.3)
Adenocarcinoma 3 (6.0) 4 (7.8)
Adenosquamous cell carcinoma 0 1 (2.0)
Small cell carcinoma 0 2 (3.9)
Undifferentiated carcinoma 0 1 (2.0)
Treatment duration (days) 49.9 (19–88) 50.6 (35–60)
External radiotherapya
Whole-pelvis dose (Gy) 30.7 (20–50.5) 31.1 (20–45)
Central shield dose 22.0 (19.8–30) 21.0 (10–21.6)
Brachytherapya
High-dose rate (Gy) 26.5 (24–30) 25.3 (20–30)
Times of chemotherapy (cycles)a 4.3 (1–5) 4.1 (1–5)
Total dose of CDDP (mg/m2)a 170.4 (30–200) 162.4 (30–200)
Number of HT treatment
1–3 – 4 (7.8)
4–6 – 47 (92.2)
Thermometry results of HT
Tmax (C) – 42.2 (40.1–44.6)
Tave (C) – 41.1 (39.6–42.5)
CEM43T90b (min) – 3.8 (0.1–46.6)
Follow-up duration (months) 59.0 (0.7–154.9) 69.2 (2.5–156.3)
aSummary of patients’ data who received the therapy.
bThis data was calculated in 47 evaluable patients with complete thermometry
data.
FIGO: International Federation of Gynecology and Obstetrics; CRT: chemoradio-
therapy; HT: hyperthermia.
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A patient flow diagram is presented in Figure 1. One
patient each in the CRT and CRTþHT groups rejected
chemotherapy; both patients were treated with RTþHT. One
patient in each group discontinued the treatment, and their
therapeutic response could not be analysed (they were cen-
sored in the survival analyses). Of 101 randomised patients,
28 died (CRTþHT, n¼ 12; CRT, n¼ 16) during the follow-up
period. In the CRTþHT group, 5 died due to local relapse, 2
due to distant metastasis, 2 due to local relapse and distant
metastasis, and 3 due to other diseases, whereas in the CRT
group, 4 died due to local relapse, 3 due to distant metasta-
sis, 6 due to local relapse and distant metastasis, and 3 due
to other diseases. Regarding the censored cases, at the time
of the last observations, in the CRTþHT group, 35 patients
were alive without progression, 1 was alive with progression
and 3 were lost to follow-up, whereas in the CRT group, 28
were alive without progression and 6 were lost to follow-up.
Thermometry results
In the CRTþHT group, the thermometry results demon-
strated a Tmax of 42.2 C ± 0.9 C (range, 40.1–44.6 C), Tave of
41.1 C ± 0.7 C (range, 39.6–42.5 C) and a CEM43T90 of
3.8min (range, 0.1–46.6min) (Table 1).
Overall survival
Figure 2 shows Kaplan–Meier curves for OS of both groups.
In the CRTþHT group, the 5-year survival rate was 77.8%
(95% CI, 62.3–87.5%), whereas that in the CRT group was
64.8% (95% CI, 48.7–77.0%). The log-rank test showed no
significant difference between the two groups (p¼ .141).
Adjusted HR (95% CI, p value) of the CRTþHT group for OS
was 0.485 (0.217–1.082, p¼ .077).
Disease-free survival
Figure 3 shows Kaplan–Meier curves for the DFS of both
treatment groups. In the CRTþHT group, the 5-year survival
rate was 70.8% (95% CI, 55.5–81.7%), whereas that in the
CRT group was 60.6% (95% CI, 45.3–72.9%). The log-rank test
showed no significant difference between the two groups
(p¼ .182). Adjusted HR (95% CI, p value) of the CRTþHT
group for DFS was 0.517 (0.251–1.065, p¼ .073).
Figure 1. CONSORT flow diagram for 101 randomised patients with locally
advanced cervical cancer.
Figure 2. Overall survival for patients treated with chemoradiotherapy or che-
moradiotherapy plus hyperthermia.
Figure 3. Disease-free survival for patients treated with chemoradiotherapy or
chemoradiotherapy plus hyperthermia.
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Local relapse-free survival
Figure 4 shows Kaplan–Meier curves for the LRFS of both
treatment groups. In the CRTþHT group, the 5-year survival
rate was 80.1% (95% CI, 66.1–88.8%), whereas that in the
CRT group was 71.0% (95% CI, 56.0–81.7%). The log-rank test
showed no significant difference between the two groups
(p¼ .247). Adjusted HR (95% CI, p value) of the CRTþHT
group for DFS was 0.475 (0.202–1.116, p¼ .087).
CR rate
After the completion of the protocol treatment, a CR was
achieved in 44 of 50 patients (88.0%) in the CRTþHT group
and in 38 of 49 patients (77.6%) in the CRT group. Fisher’s
exact test showed no significant association between CR
rates and treatment groups (p¼ .192). Further analysis using
a multivariable logistic regression model adjusted for relevant
clinical factors (age, FIGO stage and histology) indicated that
patients in the CRTþHT group were significantly more likely
to achieve a CR than those in the CRT group (OR, 3.993; 95%
CI, 1.018–15.670; p¼ .047; Figure 5).
Acute- and late-phase toxicity
Acute-phase toxicity is summarised in Table 2. In the ana-
lysed 101 patients, the presence of toxicity and RTOG grades
were similar between the two groups. Except for haemato-
logic toxicity related to standard CRT, only 1 patient in the
CRT group experienced  grade 3 adverse effects (grade 3
fatigue). Late-phase toxicity is summarised in Table 3, show-
ing similar toxicity in both groups. No blistering or fat necro-
sis related to HT was observed in the CRTþHT group.
Discussion
In the last decade, cisplatin-containing CRT has gained wide-
spread acceptance in the treatment of advanced CC after the
positive reports of five large randomised studies [2–6]. Most
reviews concluded that there was a beneficial effect of CRT
at least in patients with FIGO stage I and II malignancies.
However, in patients with a more advanced stage CC, it was
rather difficult to achieve local control with CRT alone, raising
a question whether the beneficial effect of CRT in early stage
CC could extend to a more advanced stage CC. A recent sys-
tematic review confirmed the suspicion that the improve-
ment in 5-year OS may only be 3% in patients with FIGO
stage III–IVA CC [22].
In 2010, Lutgens et al. [7] published a systematic review
comparing the combined use of HT and RT with RT alone for
treating locally advanced CC. They reported that RT com-
bined with HT yielded superior local tumour control rates
(RR, 0.56; 95% CI, 0.39–0.79; p< .001) and OS (HR, 0.67; 95%
CI, 0.45–0.99; p¼ .05) compared with those yielded by RT
Figure 4. Local relapse-free survival for patients treated with chemoradiother-
apy or chemoradiotherapy plus hyperthermia.
Figure 5. Result of logistic regression analysis to predict complete response (adjusted for age, stage and histology).
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alone. With regards to the safety analysis, it was reported
that the pooled data including 310 study patients showed no
difference in the acute treatment-related toxicity between
the two treatment groups (RR, 0.99; 95% CI, 0.30–3.31;
p¼ .99). Similarly, pooled data including 264 study patients
indicated no difference in the late toxicity between the two
groups (RR, 1.01; 95% CI, 0.44–2.30; p¼ .98). It was concluded
that RT combined with HT was more effective and caused no
additional toxicity compared with RT alone for patients with
locally advanced CC.
In 2005, Vasanthan et al. [23] published a negative result
for HT in 110 patients with FIGO stage IIB–IV CC treated with
RT; they reported no beneficial effects on either survival or
local control at a 3-year follow-up. In their study, HT was
applied using an 8-MHz capacitive system with intravaginal
electrodes in most patients. In 2013, Zolciak-Siwinska et al.
[24] reported a phase III study to investigate whether intersti-
tial HT combined with high-dose brachytherapy had any
influence on local control, DFS or acute and late side effects
in patients with advanced CC. They also concluded that HT
did not significantly influence failure or interactions with
potential prognostic factors for local control or DFS. It is pos-
sible that the HT procedure used in these two studies
resulted only in heating the cervix and not the entire pelvis,
presumably because intravaginal electrodes were used to
heat up the tumour volume. Although very high tempera-
tures can be achieved at the tumour’s intravaginal surface
with this method, temperatures may rapidly decline at the
tumour’s periphery.
From the point of view that concurrent CRT and concur-
rent whole-pelvic HT with RT both increased the
effectiveness of RT for CC, we proposed a combination treat-
ment for all three modalities: RT, chemotherapy and HT to
further improve the outcomes. We conducted the present
randomised clinical study to evaluate the effectiveness and
safety of this combination therapy compared with CRT alone.
Our results suggest that with respect to CR rates, CRT
combined with whole-pelvic HT is a potentially promising
treatment compared with CRT alone in patients with locally
advanced CC. Furthermore, our study suggests better OS and
DFS for the CRTþHT group; however, the differences
between groups were not significant. The most common side
effects were haematologic toxicity, with no difference in the
occurrence rates of grade 3 or worse adverse events in both
groups. No thermotoxicity was observed in the CRTþHT
group. Although cisplatin significantly increased the side
effects of RT, HT did not change the toxicity profile of RT.
Van der Zee et al. [8] previously reported the results of a
randomised multicentre trial evaluating CR rate and duration
of local control of RTþCT compared with RT alone in
patients with cervical, bladder or rectal cancer. In their study,
initially displayed significant difference in local control rate
between groups disappeared during the long-term follow-up
period in patients with bladder cancer. They discussed that
RT could kill enough cells to establish a clinical CR but did
not sterilise all clonogenic tumour cells, leading to such
inconsistency between short- and long-term local control of
tumours. In our study as well, initial significant difference in
CR rate turned not significant in the long-term local control
rate (LRFS). This phenomenon may be explained in the same
way as a specific characteristic of RT.
It is important to discuss the results in the context of the
study settings. The main limitation of this study was that the
effectiveness of standard CRT observed was far higher than
that assumed for the sample size calculation (CR rate of
77.6%, instead of 50%), requiring an unrealistically large dif-
ference in effect size or a much larger sample size in order
to demonstrate significance. Furthermore, regarding survival
rates, both the 5-year OS and DFS (64.8% and 60.6%, respect-
ively) in the CRT group seemed quite high considering that
73.3% (74 of 101) of the enrolled patients had FIGO stage
III–IVA CC. Such results may be due to the following two eli-
gibility criteria of our study: excluding para-aortic node-posi-
tive patients and requiring haemoglobin levels 10 g/dL.
Table 2. Acute-phase adverse events.
Number (%) of patients with RTOG grade
CRT (n¼ 50) CRTþHT (n¼ 51)
Adverse event Grade 1 Grade 2 Grade 3 Grade 4 Grade 1 Grade 2 Grade 3 Grade 4
HGB 3 (6.0) 17 (34.0) 11 (22.0) 5 (10.0) 2 (3.9) 29 (56.9) 11 (21.6) 3 (5.9)
WBC 1 (2.0) 10 (20.0) 29 (58.0) 4 (8.0) 2 (3.9) 18 (35.3) 17 (33.3) 8 (15.7)
PLAT 10 (20.0) 9 (18.0) 6 (12.0) 1 (2.0) 12 (23.5) 5 (9.8) 6 (11.8) 0
Nausea 15 (30.0) 7 (14.0) 0 0 14 (27.5) 0 0 0
Vomiting 2 (4.0) 4 (8.0) 0 0 4 (7.8) 0 0 0
Diarrhoea 16 (32.0) 7 (14.0) 0 0 15 (29.4) 2 (3.9) 0 0
Urinary 5 (10.0) 0 0 0 7 (13.7) 2 (3.9) 0 0
Weight loss 7 (14.0) 2 (4.0) 0 0 4 (7.8) 1 (2.0) 0 0
Fatigue 18 (36.0) 2 (4.0) 1 (2.0) 0 15 (29.4) 1 (2.0) 0 0
Nephrotoxicity 9 (18.0) 3 (6.0) 0 0 10 (9.9) 7 (13.7) 0 0
Blistering – – – – 0 0 0 0
RTOG: Radiation Therapy Oncology Group morbidity scale; CRT: chemoradiotherapy; HT: hyperthermia.
Table 3. Late-phase adverse events.
Number (%) of patients
CRT (n¼ 50) CRTþHT (n¼ 51)
None 42 (84.0) 43 (84.3)
Rectal bleeding 5 (10.0) 0
Ileus 0 4 (7.8)
Urinary bladder atrophy 1 (2.0) 0
Ureter stenosis 0 1 (2.0)
Vesico-vaginal fistula 0 1 (2.0)
Nephrotoxicity 1 (2.0) 0
Leg oedema 1 (2.0) 2 (3.9)
Fat necrosis – 0
CRT: chemoradiotherapy; HT: hyperthermia.
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The presence of positive para-aortic lymph nodes is a
known poor prognostic factor in patients with CC.
Retrospective studies conducted on this population have
demonstrated 5-year survival of about 30% [25].
Another known poor prognostic factor in patients with CC
having CRT is anaemia [26]. Bishop et al. investigated the
association between anaemia and clinical outcomes before
and after the introduction of CRT in such patients. For the
entire cohort, patients with haemoglobin concentrations
higher than 10 g/dL had significantly better disease-specific
survival rates than those with concentrations lower than
10 g/dL (p< .001) in a univariable analysis [27].
Considering the ethical feasibility of the present interven-
tional randomised controlled trial, we decided to set conser-
vative criteria based on aortic lymph nodes and anaemia
compared with other published single-arm studies.
Westermann et al. [28] analysed prospective survival data
for a combination of CRT and HT in 68 patients with stage
IIB–IVA CC in 2005. They also reported the same patients’
long-term survival rates in 2012 [13]. In their long-term fol-
low-up study, a 5-year OS of 66.1% (95% CI, 55.1–79.3%) and
5-year relapse-free survival rate of 57.5% (95% CI,
46.6–71.0%) were observed. In our study, 5-year OS and DFS
in the CRTþHT group were 77.8% and 70.9%, respectively,
apparently demonstrating better survival outcomes than
those reported in the Westermann et al. paper. However,
para-aortic node-positive patients were included in their
study. Moreover, in their study, low levels of haemoglobin
were used as eligibility criterion compared with those used
in ours (7.0 compared with 10.0, respectively). It seems
pertinent to interpret the results in the light of the differen-
ces in patients’ characteristics. The CR rate in 68 patients
with CC treated with CRTþHT reported by Westermann
et al. was 90% [28], which was almost the same as 88.0%
(44 of 50 patients) achieved in the CRTþHT group in our
study.
The relatively good survival outcomes in our study could
also be interpreted in the context of the biological basis for
combining HT and RT or chemotherapy, which includes two
types of interactions: direct hyperthermic cytotoxicity (at
temperatures of 42.5 C) and radio- and/or chemosensitisa-
tion (at temperatures of <43 C). Most of the tumour vol-
ume could be heated to radio- and/or chemosensitising
temperatures in the range of 40–42 C [29]. In the present
study, the average temperature was 41.1 C ± 0.7 C, which
was in the radio- and/or chemosensitising range. The mech-
anism of tumour response to CRTþHT within this range of
temperatures seems to involve the initiation of apoptosis
through the activation of one of the BAX pathways that we
have previously reported on [30]. In addition, Eppink et al.
[31] reported that HT-induced DNA repair deficiency was
enhanced by the inhibitors of the cellular heat-shock
response. Moreover, recently, it has become clear that HT
affects not only the cells in the treatment area but also the
systemic immune response [32]. These effects may as a
whole play an important role in a combined treatment with
CRT and HT.
As discussed above, the main limitation of the present
study was a small sample size for detecting significance.
However, it is difficult to enrol a large number of subjects in
HT studies. Compared with the notably high numbers of
randomised patients in chemotherapy studies [2–6], those in
HT studies are quite limited [7]. This is because low availabil-
ity of HT has so far resulted in quite a limited worldwide
application of HT treatment to CC. Indeed, there are not
many hospitals in Japan that use HT as a treatment modality
for malignancies.
Our findings need to be validated in future phase III stud-
ies or meta-analyses consisting of larger sample sizes.
Conclusions
HT combined with CRT improved the CR rate of CRT in
patients with locally advanced CC, however, it could not
improve survival outcomes. Further studies in larger samples
are warranted.
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